BioSpace News Archive

Live Conference Call and Webcast at 4:30 ET

PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlled trial (RCT) evaluating SkinTE for the treatment of diabetic foot ulcers (DFUs), which previously reported statistically significant wound closure rates of 72% for SkinTE plus the standard of care (SOC) vs 32% for the SOC alone (p=0.005).

- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) - Significant unmet need for new effective oral therapies in UC [16-September-2020] SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the EL

Data could support future efforts to make real-time CGM a standard tool for glycemic assessment in the hospital setting Real-world evidence will be gathered from healthcare providers and hospital institutions using real-time CGM with hospitalized patients SAN DIEGO--( BUSINESS WIRE )-- DexCom , Inc. ( NASDAQ:DXCM ), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever

Seqirus, a global leader in influenza prevention, today announced the publication of real-world evidence (RWE) on the company’s cell-based quadrivalent influenza vaccine (QIVc) in peer-reviewed medical journal Vaccine.

CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies

Medical education agency Avant Healthcare today announced that Arun Divakaruni, PhD, has been promoted to Chief Executive Officer.

McKesson Ventures, the venture capital arm of McKesson Corporation, announces the expansion of its leadership team, promoting Jennifer Carter and Carrie Hurwitz Williams to partners of McKesson Ventures.

Vibrent Health, a health technology company powering the future of precision health research, today announced it has been awarded a contract worth a potential value of $4.23 million from the National Institutes of Health’s (NIH) National Cancer Institute (NCI) and National Institute of Biomedical Imaging and Bioengineering (NIBIB), to develop a large-scale, data-driven approach to fight COVID-19

Arcutis Biotherapeutics, Inc. ((Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the completion of enrollment in DERMIS-1 and DERMIS-2, the Company’s pivotal Phase 3 clinical trials evaluating ARQ-151 (topical roflumilast cream)